Stock Price
28.26
Daily Change
-1.68 -5.61%
Monthly
6.48%
Yearly
5.37%
Q3 Forecast
29.70

ALKERMES reported $505.96M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
ALKERMES USD 505.96M 62.23M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
J&J USD 56.9B 6.58B Mar/2025
Malin Corporation EUR 1000K 500K Dec/2024
Merck USD 26.04B 863M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Otsuka Holdings JPY 675.84B 25.89B Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025